Protocol
An optimized intracerebroventricular injection of CD4⁺ T cells into mice

The blood-brain barrier acts as a major barrier for the entrance of most therapeutics into the brain, impeding treatment for neurological disorders. Intracerebroventricular (ICV) injection of T cells is a useful tool for cell therapy of neurological disorders including neurodegenerative and neuropsychiatric diseases and brain tumors. Here, we present an optimized ICV injection of T cells with improved injection efficiency at pathological sites within the brain parenchyma. We describe details of the surgical procedure and verification of injection via immunohistochemistry.

Highlights
Bilateral intracerebroventricular injection of T cells using an optimized needle gauge
Reduced damage and increased survival of the injected cells
Enhanced migration of the injected cells within the brain parenchyma
Protocol
An optimized intracerebroventricular injection of CD4⁺ T cells into mice

Zoe V. Taylor,¹,³,⁴ Bishnu Khand,¹,³ Angel Porgador,¹,³ Alon Monsonego,¹,³,* and Ekaterina Eremenko¹,²,³,⁵,*

¹The Shraga Segal Department of Microbiology, Immunology, and Genetics, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva 8410501, Israel
²The Department of Life Sciences, Ben-Gurion University of the Negev, Beer Sheva 8410501, Israel
³The National Institute of Biotechnology in the Negev, Zlotowski Neuroscience Center, and Regenerative Medicine and Stem Cell Research Center, Ben-Gurion University of the Negev, Beer-Sheva 8410501, Israel
⁴Technical contact
⁵Lead contact
*Correspondence: eremenkoem@gmail.com (E.E.), alonmon@bgu.ac.il (A.M.)
https://doi.org/10.1016/j.xpro.2021.100725

SUMMARY
The blood-brain barrier acts as a major barrier for the entrance of most therapeutics into the brain, impeding treatment for neurological disorders. Intracerebroventricular (ICV) injection of T cells is a useful tool for cell therapy of neurological disorders including neurodegenerative and neuropsychiatric diseases and brain tumors. Here, we present an optimized ICV injection of T cells with improved injection efficiency at pathological sites within the brain parenchyma. We describe details of the surgical procedure and verification of injection via immunohistochemistry.
For complete details on the use and execution of this protocol, please refer to Fisher et al. (2014); Strominger et al., (2018); Mittal et al. (2019); Eremenko et al. (2019).

BEFORE YOU BEGIN
© Timing: 1–2 days

Intracerebroventricular (ICV) administration of cells in mouse models is an efficient tool for exploring the therapeutic efficacy of cells injected directly into the central nervous system (CNS) and thus bypassing the blood-brain barrier. ICV injection has been implemented for the administration of stem cells for various neurological conditions (Scruggs et al., 2013; Sironi et al., 2017). Notably, a recent phase 1 study safely injected adipose-derived stromal vascular fraction (ADSVF) into the human brain ventricular system of patients with neurodegenerative disorders. The authors reported a clinical improvement or stability of AD and amyotrophic lateral sclerosis (ALS) patients (Duma et al., 2019). We thus highlight the importance of this technique which presents an advantageous route of cell administration such as chimeric antigen receptor (CAR)-T cells targeted to brain malignances (Bagley et al., 2018; Hunter and Jacobson, 2019; Majzner et al., 2019; Parker et al., 2020), or brain antigen-specific T cells targeted to amyloid plaques in mouse models of Alzheimer disease (Fisher et al., 2014; Strominger et al., 2018; Mittal et al., 2019; Eremenko et al., 2019). The protocol below describes the specific steps for injecting CD4⁺ T cells which were retrovirally transduced to express a green fluorescent protein (GFP). Although these cells were used to aid the better visualization of the injected cells, this protocol is compatible with all CD4⁺ T cells, which can be later stained with a suitable antibody to enable visualization.
Depending on your experimental needs, it is possible to inject unilaterally or bilaterally. For instance, unilateral ICV injections are suitable for cancer treatment studies (Majzner et al., 2019; Tanaka et al., 2020). As we were interested in the interaction between the injected cells and neural cells, we preferred a bilateral injection. Hence, our protocol focuses on bilateral ICV injections.

1. Sterilize all the surgical tools.
2. Prepare mice for experiment (in this protocol we used 12 weeks C57BL/6JRccHsd male mice).

   **Note:** Mice are housed under standard conditions. All procedures are performed under the approval of the Ben-Gurion University of the Negev Animal Care and Use Committee. All efforts are made to minimize suffering of the animals.

3. Setup the microinjection system.

   **Note:** Ensure the infusion pump is set to run at a rate of 1 μL/min.

4. Ensure there is a sufficient amount of oxygen in the balloon.
5. Fill the VetFlo vaporizer with isoflurane.
6. Prepare the cells for injection. In microcentrifuge tubes, prepare $0.5 \times 10^6$ CD4+ GFP T cells in complete RPMI media. Prior to injection, wash cells with 1 mL PBS and suspend in 2.5 mM PBS.

   **Note:** refer to (Eremenko et al., 2021) for the detailed protocol of isolating CD4+ T cells from mice and transduction with GFP-encoding retrovirus.

### KEY RESOURCES TABLE

| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|---------------------|--------|------------|
| Chemicals, peptides, and recombinant proteins | | |
| Isoflurane | Piramal Critical Care | NDC66794-017 |
| RPMI Medium 1640 | Gibco | 21875 |
| Fetal Bovine Serum | Gibco | 10500-064 |
| β-Mercaptoethanol (14.3 M) | Sigma-Aldrich | M3148 |
| Sodium Pyruvate (100 mM) | Biological Industries | 03-042-1B |
| MEM Non-Essential Amino Acids Solution (10 mM) | Biological Industries | 01-340-1B |
| HEPES Buffer Solution (1M) | Biological Industries | 03-025-1B |
| Penicillin-Streptomycin Solution (100x) | Biological Industries | 03-031-1B |
| BupaqR Multidose 0.3 mg/mL Veterinary (Buprenorphine) | Richter Pharma | GTIN: (01) 900411402258 |
| Ethanol 99% | Tech Romical | 19-009101-78 |
| 4% Paraformaldehyde | Electron Microscopy Sciences | 15714 |
| Sucrose | Glentham Life Sciences | GC4473 |
| O.C.T. Compound | Scigen | 4586 |
| Ethylene Glycol | ChemCruz | sc-257515A |
| Glycerol | Biolab | 000712050100 |
| Dulbecco’s Phosphate Buffered Saline, without calcium and magnesium | Biological Industries | 02-023-1A |
| Tween-20 | Sigma-Aldrich | P1379 |
| Triton X-100 | Sigma-Aldrich | T9284 |
| DAPI (4,6-diamidino-2-phenylindole) | BioLegend | 422801 |
| Anti-Fade Fluorescence Mounting Medium | Abcam | ab104135 |
| Trypan Blue Solution | Biological Industries | 03-102-1B |

(Continued on next page)
Alternatives: In theory, all reagents and resources listed in the ‘key resources table’ can be substituted with equivalent items from other suppliers; however, it should be noted that the protocol has been calibrated to the reagents listed in the above table and alternatives have not been tested on the protocol performance.

MATERIALS AND EQUIPMENT

Complete RPMI medium

| Reagent                                      | Final concentration | Amount for 500 mL |
|----------------------------------------------|---------------------|-------------------|
| Fetal Bovine Serum                           | 10% (v/v)           | 50 mL             |
| Penicillin-Streptomycin Solution (100×)      | 1 mg/mL Streptomycin, 100 U/mL Penicillin | 5 mL |
| HEPES Buffer Solution (1M)                   | 10 mM               | 5 mL              |
| MEM Non-Essential Amino Acids Solution (10 mM) | 0.1 mM              | 5 mL              |
| Sodium Pyruvate (100 mM)                     | 1 mM                | 5 mL              |
| Hepes (14.3 M)                               | 50 μM               | 1.75 μL           |
| RPMI Medium 1640                             | n/a                 | To 500 mL         |

Store at 4°C for up to one month.
STEP-BY-STEP METHOD DETAILS

ICV injection of CD4+ GFP T cells

© Timing: 40–50 min/mouse

Note: This protocol describes the procedure for injection of one mouse.

1. Anesthetize the mouse in the induction chamber filled with 2% isoflurane.

△ CRITICAL: Confirm sufficient anesthesia by assessing the foot-pinch response.

2. Once the mouse is anesthetized, clean the head area with a cotton tipped applicator soaked in 70% ethanol, avoiding the eye area.

3. Using a scalpel, make a vertical incision down the center of the head, starting between the eyes, and use a cotton tipped applicator to expose the skull and dry the area.

Note: Be careful not to damage the skull with the scalpel.

4. Place the mouse in the stereotaxic apparatus (Figure 1A), positioning the nose in the anesthesia adaptor, with a constant flow of 2% isoflurane, and tighten the ear bar on the right-hand-side until the head is firmly in place.

Note: The position of the left-hand-side ear bar is set at the start of all the injections and should not be adjusted throughout the injections.

△ CRITICAL: Place mouse over the heating pad to prevent hypothermia during the procedure.

5. Lubricate the mouse’s eyes with Viscotears Liquid Gel to prevent corneal dryness.

6. Insert the drill into the holder of the stereotaxic apparatus.

Note: Ensure the drill is correctly inserted into the holder. If not, the drill can move during drilling and damage the brain or drill the hole in the wrong area.
7. Using the drill, ensure the bregma and lambda are on the same horizontal plane. For this, gently place the tip of the drill at the bregma position. Set the dorsoventral axis to zero mm on the stereotaxic apparatus. Raise the tip of the drill and move directly down to the Lambda position. Lower the tip of the drill to the skull. If the dorsoventral axis is now ≤ 0.1 mm, the head of the mouse is straight. If not, adjust the position of the head and repeat until the bregma and lambda are on the same horizontal plane.

⚠️ CRITICAL: Ensure the head is in the correct position and stable to achieve injection to the ventricles.

8. Once the head is straight, drill two small holes in the skull, just large enough for the needle to pass through and infiltrate the brain surface. Follow the coordinates measured from the bregma, to reach the lateral ventricles: −0.5 mm in the anteroposterior axis, ± 1 mm in the mediolateral axis and −2.3 mm in the dorsoventral axis (Figure 2A).

⚠️ CRITICAL: Be careful not to cause brain damage.

**Note:** Stereotactic coordinates are optimized for 2-month-old mice and older (Allen Brain Atlas). The injection range for the dorsoventral axis is −2.3 to −3 mm. It is optimal to calibrate this coordinate for your specific mice prior to experiments, as it might change depending on the mouse strain and age. This can be achieved by injecting a dye at different coordinates in the dorsoventral axis. A successful injection is identified by the presence of the injected dye in the lateral ventricles.
9. Prepare cells for injection by adding 1 mL of PBS to a previously prepared aliquot. Centrifuge at 500 g for 5 min at 20°C. Remove the supernatant and suspend in 2.5 μL PBS.

   **Note:** Prior to experiment cells are prepared in aliquots and kept on ice.

10. Load the Hamilton syringe, holding either the 26 G or 30 G needle, with the desired treatment (here transduced CD4+ GFP T cells suspended in PBS) and place it in the arm of the stereotaxic device connected to an automated microinjection system. For control mice, inject 2.5 μL of PBS or control cells suspended in PBS, to lateral ventricle of the brain.

   **Critical:** Ensure there are no air bubbles in the syringe.

11. Position the syringe over the first hole, lower the needle until it is touching the brain, and set the dorsoventral axis to zero mm.
12. Very slowly lower the needle to −2.3 mm in the dorsoventral axis.
13. Set the infusion pump to administer the injection at a rate of 1 μL per minute.
14. Once the infusion is finished, wait for 2 min before raising the needle slowly to −1.15 mm in the dorsoventral axis. Then, wait 1 min before slowly raising the needle out of the hole.

   **Critical:** Always wait the recommended time before raising the needle and raise the needle slowly to minimize backflow.

15. Based on your experimental design, repeat the same procedure for the second lateral ventricle.
16. Close the incision using a stainless steel wound clip.

   **Note:** It is recommended to use an appropriate analgesic post-injection, for example, buprenorphine 0.05 mg/kg subcutaneously.

17. Return the mouse back to the colony.
18. Monitor the mouse until it wakes up and moves around normally.

### Preparation of brain sections for immunohistochemistry

- **Timing:** 5–6 days

19. Sacrifice the mouse 72 h post injection.
20. Perfuse the mouse with 10 mL cold PBS.

   **Note:** Perfusion was important for our experimental setup as we were interested in locating the brain-infiltrating injected cells and not the injected cells located within the brain vasculature.

21. Harvest the brain.
22. In a 15 mL centrifuge tube, suspend the brain in 4% paraformaldehyde for 48 h at 4°C.
23. Switch to 30% sucrose in PBS solution for 48 h, or until the brain has sunk to the bottom of the 15 mL centrifuge tube.

   **Pause point:** The brain can be left immersed in 30% sucrose at 4°C for up to 5 days.

24. Embed in O.C.T. compound and freeze blocks at −20°C.

   **Pause point:** O.C.T. blocks can be stored at −80°C for up to 6 months.
25. Using the microtome, cut brains to 40 μm sections.
26. In a 48 well plate, rinse the tissues in 0.5% Triton in PBS solution for 30 min.
27. Rinse tissue twice with PBST for 5 min.
28. Transfer the tissues to DAPI 1:3000 in PBS and incubate for 5 min.
29. Rinse the tissues with PBST for 5 min.
30. Transfer the tissue onto a slide. Once they have dried, add anti-fade fluorescence mounting me-
dium and cover the sections with a cover slip.
31. Image brain sections on a FLUOVIEW FV1000 laser-scanning confocal microscope.

EXPECTED OUTCOMES
To optimize the ICV injection by means of cell migration into the site of action, CD4+ GFP T cells were
ICV-injected to C57BL/6JRccHsd mice (Figure 1B). Mice were sacrificed 72 h post injection and
sagittal brain sections were obtained for immunohistochemistry analysis. Brain sections were
imaged using a FLUOVIEW FV1000 laser-scanning confocal microscope.

To rule out any influence of the needle gauge size on cell viability, CD4+ T cells were seeded (50,000
cells per well) in a 96 U-shape well plate. The cells were drawn into the syringe, holding either a 26 G
or 30 G needle, twice. The live and dead cells were counted, using trypan blue to detect the non-
viable cells, and the percent of live cells was calculated. The needle gauge size did not significantly
affect cell viability (Figure 3B).

Although the needle gauge size had no significant effect on cell viability, an increased frequency of
injected cells was observed in the brain parenchyma using the 30 G, as compared with the 26 G size
needle (Figure 3C). Thus, while optimizing the injection procedure, we have concluded that 1) the
30 G needle size increases the frequency of the injected cells at the site of action, and 2) the smallest
drill head suitable for the needle gauge size should be used to minimize the backflow.

LIMITATIONS
One of the main limitations of ICV injection is the lengthy time per mouse, making it laborious and
time consuming. Depending on the facility and personnel availability, we suggest to adjust the
cohort size performed per day. It is also essential to ensure that the mice are not away from the an-
imal facility for a prolonged duration. The mice should have free access to food and water.

The syringe should be thoroughly washed with 70% ethanol, PBS and then clean PBS between injec-
tions to avoid cross contamination of treatments. The double PBS washing reduces the tendency for
salts sticking to the inside of the syringe. The proper washing procedure also reduces the risk of
excess fluid being held in the syringe and injected to the next mouse. It is also important to note
that the cells should only be drawn into the syringe once. If cells are repeatedly drawn into and
released from the syringe, cell viability may be reduced.

We advise using isoflurane as the anesthesia as it provides effective short-term anesthesia effects. It
is possible to use an alternative anesthesia, such as a ketamine/xylazine regimen, but this comes with
a prolonged recovery time and an increased risk of hypothermia. If ketamine/xylazine is preferred,
mice should be closely monitored until they regain consciousness and move around by themselves.
It is also recommended to provide heat, such as a heating pad, during the recovery time. A rectal
thermometer can be used to monitor the body temperature during the procedure and recovery
time.

As it may be necessary to divide the cohort over several days and the injection time of each batch of
cells may take a few hours, it is essential to check the viability and homogeneity of the cell samples
throughout the experiment. This can be done via cell quality validation with flow cytometry analysis
performed on the day of injection.
**Troubleshooting**

**Problem 1**
Failure to correctly mount mouse onto stereotactic apparatus (steps 1 and 4).

**Potential solution**
Ensure the mouse is fully anesthetized before transferring it to the stereotactic apparatus.

Confirm sufficient anesthesia by assessing the foot-pinch response.

Set position of left ear bar at start of all the injections and only adjust the right ear bar to secure head in position.

Ensure the mouse’s nose is securely in the anesthesia adaptor to ensure the mouse remains anesthetized throughout the procedure.

**Problem 2**
Failed injection due to incorrect injection site (step 6, 7 and 8).

**Potential solution**
Confirm you can clearly visualize the bregma and lambda.

Ensure the mouse head is mounted straight by utilizing the bregma and lambda as reference points.
Ensure the head is stable by gently pressing on the top of the head, once mounted. This ensures the head does not move during the drilling and injection steps.

Ensure the drill is inserted into the holder correctly.

**Problem 3**
Backflow of the injected cell suspension (steps 8 and 12–14).

**Potential solution**
Use the smallest drill head size suitable for the needle.

Inject at a flow rate of 1 μL/min.

Once the injection is finished, wait 2 min before slowly raising the needle to −1.15 mm in the dorso-ventral axis. Then wait a further minute before slowly raising the needle out of the hole.

Insert and raise the needle slowly to help decrease the backflow rate.

**Problem 4**
Bleeding due to incorrect drilling of the skull (steps 6 and 8)

**Potential solution**
Ensure the drill is inserted correctly into the holder. Otherwise, the drill can move during drilling resulting in the hole being drilled in the wrong area or damage to the brain.

It is important not to drill too deep to prevent puncturing the skull resulting in bleeding and inflammation of the brain.

If bleeding does occur due to drilling, use a gauze to apply pressure to the injection site until the bleeding has stopped.

If brain is badly damaged, exclude the mouse from the experiment.

**Problem 5**
Death of mouse (steps 1, 4, and 18).

**Potential solution**
Ensure to use the correct isoflurane concentration, we use 2%.

It is also possible to use alternative anesthesia, for example, ketamine xylazine, but recovery time is longer and comes with a higher risk of hypothermia.

Place mouse on heat pad during procedure to prevent hypothermia.

Monitor mice post procedure until they wake up and are moving on their own.

**Problem 6**
Decreased viability of cells if left on ice too long (step 9).

**Potential solution**
If many mice need to be injected, prepare the cells in different batches throughout the day to prevent them being on ice for too long.
Depending on your experimental needs, it may be an option to decrease the injection time per mouse by injecting unilaterally.

Prepare aliquots of cells in culture media, only wash and suspend in PBS directly prior to injection.

Ensure to sufficiently clean the syringe with ethanol 70% and PBS between injections.

**RESOURCE AVAILABILITY**

**Lead contact**

Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Ekaterina Eremenko (eremenkoem@gmail.com).

**Materials availability**

This study did not generate new unique reagents.

**Data and code availability**

This protocol did not generate/need datasets.

**ACKNOWLEDGMENTS**

This research was supported by funding from The National Institute for Biotechnology in the Negev Ltd., and The Ministry of Science and Technology (grant # 3-16148). The graphical abstract and Figures 1 and 3 were created with BioRender.com.

**AUTHOR CONTRIBUTIONS**

Z.V.T., E.E., and B.K. performed the experiments. Z.V.T., E.E., A.P., and A.M. designed the experiments and wrote the manuscript. All authors read, revised, and approved the manuscript.

**DECLARATION OF INTERESTS**

The authors declare no competing interests.

**REFERENCES**

Bagley, S.J., Desai, A.S., Linette, G.P., June, C.H., and O’Rourke, D.M. (2018). CAR T-cell therapy for glioblastoma: Recent clinical advances and future challenges. Neuro. Oncol. 20, 1429–1438.

Duma, C., Kopyov, O., Kopyov, A., Berman, M., Lander, E., Elam, M., Arata, M., Weiland, D., Cannell, R., Caraway, C., et al. (2019). Human intracerebroventricular (ICV) injection of autologous, non-engineered, adipose-derived stromal vascular fraction (ADSVF) for neurodegenerative disorders: results of a 3-year phase 1 study of 113 injections in 31 patients. Mol. Biol. Rep. 46, 5257–5272.

Eremenko, E., Mittal, K., Berner, O., Kamenevsky, N., Nemirovsky, A., Elyahu, Y., and Monsonego, A. (2019). BDNF-producing, amyloid β-specific CD4 T cells as targeted drug-delivery vehicles in Alzheimer’s disease. EBioMedicine 43, 424–434.

Eremenko, E., Taylor, Z.V., Khand, B., Zaccai, S., Porgador, A., and Monsonego, A. (2021). An optimized protocol for the retroviral transduction of mouse CD4 T cells. STAR Protocols. https://doi.org/10.1016/j.xpro.2021.100719.

Fisher, Y., Strohmer, J., Biton, S., Nemirovsky, A., Baron, R., and Monsonego, A. (2014). Th1 polarization of T cells injected into the cerebrospinal fluid induces brain immunosurveillance. J. Immunol. 192, 92–102.

Hunter, B.D., and Jacobson, C.A. (2019). CAR T-cell associated neurotoxicity: mechanisms, clinicopathologic correlates, and future directions. J. Natl. Cancer Inst. 111, 646–654.

Majner, R.G., Theruvath, J.L., Nellan, A., Heitzeneider, S., Cui, Y., Mount, C.W., Rietberg, S.P., Linde, M.H., Xu, P., Rota, C., Sottile, E., Labanieh, L., Lee, D.W., et al. (2019). CAR T cells targeting B7-H3, a pan-cancer antigen, demonstrate potent preclinical activity against pediatric solid tumors and brain tumors. Clin. Cancer Res. 25, 2560–2574.

Mittal, K., Eremenko, E., Berner, O., Elyahu, Y., Strohmer, J., Apelblat, O., Nemirovsky, A., Spiegel, I., and Monsonego, A. (2019). CD4 T cells induce A subset of MHCII-expressing microglia that attenuates Alzheimer pathology. iScience 16, 298–311.

Parker, K.R., Migliorini, D., Perkey, E., Yost, K.E., Bhaduri, A., Bagga, P., Haris, M., Wilson, N.E., Liu, F., Gabunia, K., Scholler, J., Montine, T.J., et al. (2020). Single-cell analyses identify brain mural cells expressing CD19 as potential off-tumor targets for CAR-T immunotherapies. Cell 183, 126–142.e17.

Scruggs, B.A., Zhang, X., Bowles, A.C., Gold, P.A., Semon, J.A., Fisher-Perkins, J.M., Zhang, S., Bonvillain, R.W., Myers, L., Li, S.C., Kalu, E.V., and Bunnell, B.A. (2013). Multipotent stromal cells alleviate inflammation, neuropathology, and symptoms associated with globoid cell leukodystrophy in the twitcher mouse. Stem Cells 31, 1523–1534.

Sironi, F., Vallarola, A., Violatto, M.B., Talamini, L., Freschi, M., De Gioia, R., Capelli, C., Agostini, A., Mascatelli, D., and Tortarolo, M. (2017). Multiple intracerebroventricular injections of human umbilical cord mesenchymal stem cells delay motor neurons loss but not disease progression of SOD1G93A mice. Stem Cell Res 25, 166–178.

Strominger, J., Elyahu, Y., Berner, O., Becknow, J., Mittal, K., Nemirovsky, A., and Monsonego, A. (2018). The choroid plexus functions as a niche for T-cell stimulation within the central nervous system. Front. Immunol. 9, 1–15.

Tanaka, K., Kato, I., Tanaka, M., Morita, D., Matsuda, K., Takahashi, Y., Nakahata, T., Umeda, K., Hiramatsu, H., Adachi, S., et al. (2020). Direct delivery of piggyBac CD19 CAR T cells has potent anti-tumor activity against ALL cells in CNS in a xenograft mouse model. Mol. Ther. Oncol. 7, 37–46.